2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence function
2022
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2021
The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers
Rybkin A, Kang JJ, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Zakeri K, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, McBride SM, Tsai CJ, Riaz N, Lee NY. The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers. Head & Neck 2021, 43: 3796-3809. PMID: 34585792, PMCID: PMC9414892, DOI: 10.1002/hed.26879.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Squamous CellChemoradiotherapyHead and Neck NeoplasmsHumansNeoplasm Recurrence, LocalOropharyngeal NeoplasmsRetrospective StudiesConceptsRadiation treatment breaksOropharyngeal squamous cell carcinomaOverall treatment timeTreatment breaksClinical outcomesDefinitive concurrent chemoradiotherapySquamous cell carcinomaConcurrent chemoradiotherapyOPSCC patientsOropharyngeal cancerDisease failureCell carcinomaNeck cancerCancer recurrenceConsecutive cohortMultivariate analysisSignificant associationPatientsCancerFurther investigationProlongationDaysOutcomesNumerous studiesChemoradiotherapyTERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesisProton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Lee A, Kang J, Bernstein H, Marqueen K, Neal B, Kelly C, Dickson M, Tsai C, Tap W, Singer S, Alektiar K, Lee N. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine 2021, 10: 4221-4227. PMID: 34085781, PMCID: PMC8267151, DOI: 10.1002/cam4.3646.Peer-Reviewed Original ResearchConceptsLocal progression-free survivalMetastatic sarcomaSystemic therapyQUAD ShotOverall survivalUnivariate analysisPalliative responseMedian local progression-free survivalGrade 3 acute toxicityFurther systemic therapyProgression-free survivalConcurrent systemic therapyProton therapyCommon histologyMedian followProton RTTreatment optionsRadiation therapyPatientsLocal controlSarcomaTherapyRegimenProton radiotherapyAcute toxicity
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpointWrong to be Right
Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/coc.0000000000000216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceCohort StudiesDatabases, FactualDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesRisk AssessmentSalvage TherapySurvival AnalysisTreatment OutcomeConceptsSalvage radiation therapyRadical prostatectomyT stageCox multivariate analysisIntrinsic risk factorsIatrogenic failuresPostoperative PSASRT PSASalvage radiationBiochemical progressionIndependent predictorsLocal recurrencePreoperative PSARelapse rateBiochemical relapseKaplan-MeierBiochemical recurrenceSurgical approachRP patientsRisk factorsSurgical techniqueGleason gradeRadiation therapySurgical pathologyConsecutive rises
2014
Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy
Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy. Journal Of Urology 2014, 193: 1532-1538. PMID: 25463990, PMCID: PMC4527538, DOI: 10.1016/j.juro.2014.11.017.Peer-Reviewed Original ResearchConceptsUltrasensitive prostate specific antigenProstate-specific antigenInitial prostate-specific antigenPostoperative prostate-specific antigenBiochemical relapseSpecific antigenHigh riskRadical prostatectomyPostoperative radiotherapyT stageGleason gradeMultivariate analysisProstate-specific antigen (PSA) recurrenceEventual biochemical failureSpecific antigen recurrenceCox multivariate analysisTraditional risk factorsConventional prostate specific antigenBiochemical failureIdentifies patientsMedian followupMargin statusPathology findingsKaplan-MeierPositive margins